Neos Therapeutics to Participate in Two December Conferences

Tuesday, November 28, 2017 1:01 PM UTC

DALLAS and FORT WORTH, Texas, Nov. 28, 2017 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that management will participate in two upcoming conferences in December.

Management will be available for one-on-one meetings at the Global Mizuho Investor Conference (MIC) 2017 on Tuesday, December 5, 2017 in New York, NY.
Vipin K. Garg, Ph.D., President and CEO, will participate in a fireside chat at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017 at 3:00 p.m. ET in New York, NY.

A live webcast of the BMO presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.

About Neos Therapeutics

Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex^®1, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

¹Tussionex^® is a registered trademark of the UCB Group of Companies.

Contacts:

Richard Eisenstadt		Sarah McCabe
Chief Financial Officer		Vice President
Neos Therapeutics		Stern Investor Relations, Inc.
(972) 408-1389		(212) 362-1200
[email protected]		[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Neos Therapeutics to Participate in Two December Conferences

Editor's Picks

Welcome to EconoTimes